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Abstract
It has been 50 years since chronic granulomatous disease was first reported as a disease which
fatally affected the ability of children to survive infections. Various milestone discoveries from the
insufficient ability of patients' leucocytes to destroy microbial particles to the underlying genetic
predispositions through which the disease is inherited have had important consequences. Longterm
antibiotic prophylaxis has helped to fight infections associated with chronic granulomatous disease
while the steady progress in bone marrow transplantation and the prospect of gene therapy are
hailed as long awaited permanent treatment options. This review unearths the important findings
by scientists that have led to our current understanding of the disease.
Early CGD History
In 1954, at an annual meeting of the Society for Pediatric
Research, Janeway and colleagues [1] first reported five
cases of children with elevated serum gamma globulin
levels that suffered from recurrent infections. At this time,
the basis for their susceptibility was not identified. Three
years later, four boys with hypergammaglobulinemia, suf-
fering recurrent infections of the lungs, lymph nodes, and
skin, with a presence of granulomatous lesions were
described by Bridges et al. [2]. Landing and Shirkey [3]
also described 2 boys with recurrent infection who had
infiltration of visceral organs by pigmented lipid histio-
cytes. It was here that a new syndrome "fatal granuloma-
tous disease of childhood" was first described. The disease
was so called to depict the syndrome of recurrent infec-
tions whose sufferers invariably died in the first decade of
life. Quie and colleagues further went on to demonstrate
the defective bactericidal capacity of the polymorphonu-
clear leukocytes from affected males, thus meaning that
these patients were unable to ward off infections [4]. Over
the next ten years little more was known about the dis-
ease. Treatments using erythromycin and novobiocin
antibiotics, along with regular surgical drainage, increased
the survival rate of 4 years to one of 12 years. The use of
the word 'fatal' was subsequently dropped from the clini-
cal synonym as patient life expectancy increased with
improved medicines and diagnostics, and was classified as
the more commonly known chronic granulomatous dis-
ease (CGD).
A genetic enzyme disorder
In the 1960s, studies on patient blood confirmed CGD to
be a disease of impaired phagocytes. Holmes et al. [5] sug-
gested that the cellular defect was 'a deficiency in one
enzyme, either located within polymorph lysosomes or
among those responsible for metabolic adaptations nec-
essary for the normal function of the lysosomes or lyso-
somal enzymes'. This caused skepticism from some
scientists who thought a deficiency of a single enzyme of
this type was unlikely and that a less specific factor in the
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phagocytic process was responsible [6]. It was also
thought that because the disease occurred in boys and was
familial that the defect was X-linked. However, reports of
the disease in females began to emerge, thereby revealing
an autosomal recessive inheritance of the same phenotype
[7,8]. It was then that Nathan and Baehner [9] showed
that leukocytes from CGD patients, unlike normal human
leukocytes, did not reduce nitroblue tetrazolium (NBT), a
compound that converts to insoluble blue formazan
product upon reduction by the superoxide anion (O2-.).
This phenomenon was rapidly established as a sensitive
clinical screening test for CGD that is still used today.
Over the next twenty years, over 150 scientific papers had
been published reporting cases of patients with CGD
describing their symptoms and similarities to other gran-
uloma forming diseases. It was observed that CGD leuco-
cytes could ingest micro-organisms but failed to kill the
organisms responsible for the infections. Phagocytosis is
normally accompanied by a marked increase in oxidative
metabolism and studies had shown that NADPH oxidase
was the respiratory enzyme responsible for bactericidal
activity [10]. The hexose monophosphate shunt is respon-
sible for generating reduced NADPH [10]. The critical
deficiency in CGD cells is to generate O2-. and other reac-
tive oxygen species such as hydrogen peroxide (H2O2)
[11]. The importance of H2O2 was illustrated by the fact
that some bacterial species, such as Streptococci, that pro-
duces its own H2O2, could be killed by CGD leucocytes
[12]. Following further corroboration that the deficiency
in CGD was caused by a defect in the NADPH oxidase sys-
tem in CGD patients, scientists began to research the for-
mation of the free radical form of oxygen, O2-., produced
by NADPH oxidase during its respiratory burst, and
showed that whereas normal leucocytes generated O2-.
during phagocytosis, CGD phagocytes were not able to do
this [13-15].
Speculation that a b-type cytochrome may also be
involved in this O2-. generating activity began in 1979
from observations that a cytochrome-b associated with a
particulate fraction of normal neutrophils, was absent
from the neutrophils from some, but not all, patients with
CGD [16]. Described as the heme-containing protein,
cytochrome-b558 was proposed as a primary component
of the microbicidal oxidase system of phagocytes. A mul-
ticenter European evaluation of its incidence and rele-
vance was conducted in London [17] where it was found
to be undetectable in all 19 of the men studied in whom
the defect appeared to be located on the X chromosome.
Thus cytochrome-b558 was hailed an important compo-
nent of the microbicidal NADPH oxidase system and pro-
vided insight into its role in the enzyme complex.
Borregaard and colleagues [18] demonstrated that
approximately 90% of the cytochrome-b558 resides in the
membrane of the specific granules of unstimulated
human neutrophils and that the cytochrome-b558 translo-
cates to the plasma membrane when the cells are stimu-
lated. The authors speculated that the observed
translocation was essential to the formation of an electron
transport chain which generates O2-., the single precursor
from which all microbicidal oxidants ultimately arise.
Unravelling the NADPH oxidase enzyme
The 1980s saw the formation of a disease-gene relation-
ship. Linkage analysis using cloned, polymorphic DNA
probes suggested a proximal location (Xp21) within CGD
families [19]. Cytochrome-b558  was, so far, the only
clearly defined component of this oxidase system and its
absence provided the molecular basis of X-linked CGD, in
which a profound predisposition to infection resulted
from complete failure of this respiratory burst. Within a
month of each other in March 1987, three separate groups
working on the constituents of the phagocyte NADPH oxi-
dase (phox) enzyme published their findings. Segal was
the first to find that cytochrome-b558 had two subunits – a
23 K protein and the previously described 76–92 K glyco-
protein. Reporting that the subunits were closely linked
and remained associated with the heme of cytochrome-
b558, neither protein was detected in the cells of five
patients with X-linked CGD, whereas both were present in
two with the autosomal recessive inheritance form of this
disease. This was the first finding substantiating what we
now know are the smaller and larger subunits of the
phagocyte cytochrome-b558 heterodimer (p22phox and
gp91phox respectively) [20]. Umei and colleagues then
discovered a 66 kDa component [21] particulate in oxi-
dase fractions obtained from patients with CGD, regard-
less of whether they contained cytochrome-b558 or not,
and Curnutte and Scott [22] also found a soluble activa-
tion factor that was localized entirely to the cytosolic frac-
tion with a mass of approximately 40 kDa. Later studies
confirmed the exact molecular weight to be 47 kDa
(p47phox).
In 1981, a variant or atypical X-linked form of CGD was
described [23] whereby the gp91phox subunit was found
in normal levels but only able to function partially. Cur-
nutte [24] suggested that these rare type of CGD cases
were allelic variants and patients with this uncommon
cytochrome-b558-positive X-linked form of CGD have
been reported by others since [25,26]. Today, classical X-
linked CGD refers to cases where there is no respiratory
burst activity demonstrable in a patient's neutrophils and
the gp91phox subunit is absent. Autosomal recessive
CGD is diagnosed when burst activity is abnormal and
one of the other NADPH oxidase subunits is deficient.
Variant or atypical CGD is diagnosed when a patient's
neutrophils have demonstrable amounts of NADPH oxi-Medical Immunology 2006, 5:4 http://www.medimmunol.com/content/5/1/4
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dase subunit present but oxidaitive burst activity is not at
a level sufficient to fight off infection.
In 1986, the gp91phox subunit was first cloned [27],
encoded from the CYBB gene, although little homology
with other known protein sequences shed inadequate
light on its function at the time. This was a huge advance
in the molecular understanding of CGD and led to the
development of animal models and the ability to deter-
mine what controls gp91phox function and activity; as
well as being fundamental to current gene therapy devel-
opment. Subsequently, by screening a promyelocytic
leukemia cDNA library, Volpp et al. (1989) cloned and
sequenced a cDNA encoding the 47-kD component of the
NADPH oxidase system [28], Leto et al. (1990) [29]
cloned a p67phox cDNA while Dinauer et al. [30]
reported the structure of the gene for the 22-kD light chain
of cytochrome-b558 and its chromosomal location, which
served as a foundation for the analysis of genetic abnor-
malities at this locus in CGD. The cloning of p40phox by
Wientjes et al. [31] provided important insights into its
interactions with p67phox and p47phox in the cytosol. It
was first suspected in the late 1980s that a GTPase might
play a role in NADPH oxidase activation when it was dem-
onstrated that guanine nucleotides were able to stimulate
oxidase activity. The GTPase was subsequently identified
and cloned as Rac1 or Rac2 and it is now clear that its pres-
ence is absolutely required for full oxidase function [32].
Mutations in the X-linked and autosomal 
recessive forms of CGD
Research into CGD has improved our knowledge of the
normal NADPH oxidase system. In some cases, the iden-
tification of specific mutations has provided insights at a
molecular level. Most patients with CGD have mutations
in the CYBB gene that encodes gp91phox, located at
Xp21.1. Since the discovery of the CYBB gene no single
mutation appeared to be responsible and a flood of
research on mutations ensued, reporting large and small
deletions, frameshifts and other mutations. The genetics
of many hundreds of families with CGD were investigated
and recounted and a mutation registry database for X-
linked and autosomal recessive CGD was set up by Dirk
Roos and MaunoVihinen from the University of Tampere
in Finland [33] which presently lists 304 mutation entries
from 267 unrelated families showing about 204 unique
molecular events. Most of the X-linked mutations (174)
are in the N-terminal domain. The number of mutations
in other domains report: 50 in the FAD domain, 49 in the
NADPH domain, 7 in the loop region, 3 in the upstream,
the non-coding region before initiation codon, and 20
undefined gross deletions. The most common mutations
are nonsense mutations (81), followed by missense muta-
tions (78), frameshift deletions (42), intron mutations
(34), frameshift insertions (30), and inframe deletions
(6) [33,34].
Autosomal recessive CGD arises from mutations occur-
ring in either the p67phox, p47phox or p21phox phago-
cyte oxidase proteins. Mutations in the NCF2 gene which
encodes the p67phox represents about 5% of CGD cases
whereas deficiencies of NCF1 which encodes p47phox
represents about a quarter of all cases of CGD [35]. Unlike
other CGD subtypes, in which there is great heterogeneity
among mutations, 97% of affected alleles in patients with
p47phox deficiency carry a characteristic 2-base pair delt-
aGT deletion in the NCF1 gene [36]. p22phox mutations
are less common and 2 novel nonsense and missense
mutations in the CYBA gene have been described [37].
Mutations in the corresponding genes responsible for the
different genetic subgroups of CGD are shown in Table 1.
Genetic defects in Rap1a, Rac, or p40phox havenot been
reported in CGD [38], however, a dominant-negative
mutation in the hematopoietic-specific Rac2 GTPase was
identified in an infant with severe neutrophil dysfunction
and a predisposition to bacterial infections similar to
CGD and leukocyte adhesion deficiency [39].
Activation of the NADPH oxidase complex
The dormant oxidase consists of both cytosolic and mem-
brane-bound components, but the active O2-. generating
complex is confined to the plasma membrane [1,2]. This
implies that the cytosolic components must either act in a
signaling capacity by modifying the membrane compo-
nents, or that they must become directly associated with
the membrane via a translocation process.
The 47 kDa phosphoprotein was found in both the
cytosol and membranes after stimulation of neutrophils
with phorbol myristate acetate and the phosphoprotein
Table 1: Classification of CGD subunits.
CGD gene Genetic Transmission Frequency (%)
gp91phox (CYBB) X-linked 65
p47phox (NCF1) Autosomal recessive 25
p67phox (NCF2) Autosomal recessive 5
p22phox (CYBA) Autosomal recessive 5
Mutations can occur in one of four NADPH oxidase subunits which give rise to X-linked or autosomal recessive CGD. The approximate 
frequencies of case occurrence are shown, with figures extrapolated from Clark et al. [35] and Dineaur et al.[38].Medical Immunology 2006, 5:4 http://www.medimmunol.com/content/5/1/4
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was detected in the cytosol preceding its detection in
membranes [40]. Activation of the neutrophil oxidase sys-
tem appeared to be dependent upon phosphorylation of
the cytosolic 47 kDa protein [41], and incomplete phos-
phorylation was found to lead to failure of the subunit to
translocate to the membrane for interaction with other
membrane components of the oxidase. In intact neu-
trophils it was conclusively demonstrated that both
p47phox and p67phox translocate to the membrane dur-
ing activation of the respiratory burst [42]. This transloca-
tion was also normal in the variant X-linked form of CGD
in which cytochrome-b558 is present but does not transfer
electrons, demonstrating that the absence of translocation
in other forms of CGD is not a secondary effect of the fail-
ure to generate O2-. [43]. Ding and colleagues [44] were
unable to detect any alterations in the protein kinases in
CGD neutrophils that could explain these defects in phos-
phorylation of p47phox. The GTP-binding protein Rac2
was also found to migrate from the cytosol to the mem-
brane cytoskeleton with p67phox and p47phox, indicat-
ing that Rac2 behaves like a dedicated component of the
respiratory burst oxidase [45]. A schematic of NADPH oxi-
dase activation is shown in Figure 1.
The primary biochemical defect in CGD that leads to
impaired microbicidal activity was thought to be failure of
phagocytes to generate sufficient quantities of reactive
oxygen species (ROS), which are responsible for the so-
called respiratory or oxidative burst. These compounds
are derived from initial production of the extremely unsta-
ble and weakly bactericidal O2-., which subsequently is
dismutated into H2O2., In the presence of myloperoxidase
which is delivered by primary granules into the phago-
somes, H2O2 gives rise to more potent oxidants such as
oxyhalides (most frequently hypochlorous acid), the
hydroxyl radical (OH-.), or singlet oxygen (O-.) [46]. The
high concentrations of ROS generated within the phago-
some were thought to kill directly because of their oxidiz-
ing capacity.
The fact that phagocytes kill microbes through toxic oxy-
gen radicals and their metabolites provided much of the
biological basis for theories relating the toxicity of oxygen
radicals to the pathogenesis of CGD. However, recent evi-
dence [47] indicates that microbes might be killed by pro-
teases, activated by the oxidase through the generation of
a hypertonic, K+-rich and alkaline environment in the
Schematic representation of the NADPH oxidase enzyme Figure 1
Schematic representation of the NADPH oxidase enzyme. The integral membrane of the phagocyte consists of two 
subunits: p22phox and gp91phox which respectively produce the smaller and larger chain of the cytochrome-b558. Two 
cytosolic subunits: p67phox and p47phox; a p40phox accessory protein and a Rac-GTP binding protein then translocate to the 
cell membrane upon cell activation to form the NADPH oxidase complex which generates a respiratory burst. Superoxide can 
react to form hydrogen peroxide and hypochlorus acid, which together participate in bacterial killing.
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phagocytic vacuole. Thus, the role of ROS in the killing
process is not as direct as previously thought, although,
ROS are necessary to increase phagosomal osmolarity.
Mice made deficient in neutrophil-granule proteases, but
normal in respect of superoxide production and iodinat-
ing capacity, were unable to resist staphylococcal and can-
didal infections, suggesting that proteases are primarily
responsible for the destruction of the bacteria [48]. Fur-
ther research then showed that microbial killing and
digestion were abolished when the BKCa channel was
blocked, revealing an essential and unexpected function
for this K+ channel in the microbicidal process [48].
Defective inflammatory responses
In addition to recurrent life-threatening infections,
patients often develop sterile granulomas in hollow
organs, liver, lymphoid tissue and skin, without clinical
evidence of infections [49]. The mechanisms involved in
this aberrant inflammatory response are unknown.
Inflammatory responses are finely balanced between pro-
inflammatory and anti-inflammatory mediators and are
important in generating an effective primary immune
response and in clearing infection. Cultured cells from
CGD patients have been shown to be deficient in their
ability to produce anti-inflammatory mediators [50] and
that neutrophils from these patients are defective in their
ability to expose phosphatidylserine (PS), which is a rec-
ognition factor for phagocytic cells to clear apoptotic cell
bodies. The externalized PS molecules on apoptotic cells,
and subsequent internalization and degradation of apop-
totic cells, is crucial to prevent the activation of an inflam-
matory response and persistence of inflammatory cells
that do not undergo apoptosis and are not phagocytosed
leads to an increase of necrosis and release of toxic granule
contents that can cause chronic inflammation. Recently,
we have shown that the rate of phagocytosis of apoptotic
CGD neutrophils is also reduced (unpublished observa-
tions). It is not known why this occurs and further studies
of the mechanisms of neutrophil apoptosis are necessary
to understand the pathophysiology of its deficiency in
CGD. Failure to successfully resolve inflammation can
underlie the persistent inflammatory responses in CGD
patients, as manifested by colitis, urinary tract obstruc-
tion, dysphagia, gastric outlet obstruction and chori-
oretinitis.
Interferon-gamma therapy for CGD
In the late 1980s the potential of interferon gamma was
investigated as a prophylactic therapeutic agent for CGD
as preliminary studies in CGD patients demonstrated that
brief in vitro or in vivo administration of recombinant
IFN-γ (rIFN-γ) significantly enhanced phagocyte O2-. pro-
duction and Staphylococcus aureus bacterial killing. In two
patients with variant X-linked CGD, rIFN-γ treatment in
vivo was also associated with increased spectral levels of
neutrophil cytochrome-b558  [51]. Subsequent studies
found little evidence for transient increases in O2-. pro-
duction following rIFN-γ therapy, where O2-. production
was not sustained or associated with any change in cyto-
chrome-b558 levels [52]. In some patients, rIFN-γ therapy
was associated with the appearance of a small subset of
circulating monocytes (1% to 20%) that were NBT-posi-
tive, suggesting that one possible mechanism by which
rIFN-γ may benefit CGD patients was by partially correct-
ing the respiratory burst defect in a subset of monocytes.
Although it seemed that rIFN-γ therapy in the vast major-
ity of CGD patients was not due to enhanced neutrophil
NADPH oxidase activity, the mechanism of rIFN-γ action
in CGD patients remains unknown. A study by Ahlin et al.
[53] showed that rIFN-γ treatment of patients with CGD
was associated with augmented production of nitric oxide
by polymorphonuclear neutrophils. A comprehensive fol-
low up study of 76 patients with CGD who received rIFN-
γ found that its prolonged use in patients with CGD
appeared to be safe and showed persistent reduction in
the frequency of serious infection and mortality [54].
Recent studies looking at the cytochrome-b558  gene
expression in Brazil [55] and Japan [56] found increased
total messenger RNA (mRNA) levels in the CGD patients'
cells suggesting that rIFN-γ improved mRNA splicing and
concluded that rIFN-γ partially corrects a nuclear process-
ing defect. These studies have lead to the consensus that
only rare variants with splice site mutations can be
improved with rIFN-γ therapy. rIFN-γ therapy is relatively
expensive due to the high cost of recombinant human
interferons, the large doses and lengthy course of admin-
istration necessary to achieve maximum response rates in
recipients, and is not routinely administered prophylacti-
cally in Europe.
A cure for CGD
Following the successful use of allogeneic bone marrow
transplants to treat children with severe combined
immune deficiency [57]. Goudemand and colleagues [58]
made the first attempt to treat a case of CGD using bone
marrow transplantation (BMT). Although in this case the
transplant failed after two months due to tissue rejection
recent advances in BMT expertise and technology have led
to BMT becoming a successful treatment option for CGD
patients. A recent review of cases revealed that 20 of 24
CGD patients are alive and disease free 1–7 years after
transplant [59]. BMT can be successfully performed for
CGD and remains an attractive option for children who
have an HLA matched sibling donor and useful in selected
very severe cases in which prophylactic therapy is prob-
lematic, although in many cases donors can be hard to
find.
Gene therapy involves the permanent genetic correction
of hematopoietic stem cells in which a vector is used toMedical Immunology 2006, 5:4 http://www.medimmunol.com/content/5/1/4
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carry the corrective gene into the cells which are then re-
introduced to the body. CGD is a particularly good candi-
date for gene therapy because low levels of functional
phagocytes are expected to provide significant activity
against pathogenic microbes. In 1992, Thrasher and col-
leagues [60] used cell lines from patients with defective
p47phox as targets for reconstitution using retrovirus-
mediated gene transfer, thus creating an in vitro model of
gene therapy for this disease. This was shortly followed by
retrovirus-mediated gene transfer of gp91phox cDNA
from patients with X-linked CGD to reconstitute func-
tional NADPH oxidase activity in B-cell lines [61]. The
reconstitution of NADPH oxidase activity in cell lines
from three unrelated patients, each of which had a differ-
ent molecular defect in the gene, suggested that X-CGD
would be a suitable disease for treatment by gene therapy.
CGD mouse models have been developed by gene disrup-
tion, and preclinical studies on these animals using
recombinant retroviral vectors have demonstrated recon-
stitution of functionally normal neutrophils and
increased resistance to pathogens such as Aspergillus fumi-
gatus, Burkholderia cepacia and Staphylococcus aureus [62].
These studies were extended to human cell lines, where
retroviral vectors to restore NADPH oxidase activity was
tested in human myeloid leukemic cell lines defective in
superoxide production, as well as in primary CD34+ cells
obtained from X-CGD patients. It was shown that the
level of O2-. production in phagocytes derived from trans-
duced cells was 69% of normal levels [63]. In the US,
CGD gene therapy clinical trials targeted both the most
common X-linked form of CGD as well as the autosomal
recessive forms of this disease. Malech and colleagues [64]
isolated hematopoietic stem cells from four X-CGD
patients, infected the cells with a retrovirus containing the
normal gp91phox gene, grew the transfected cells in cul-
ture, and infused them back into the original patients
from which the cells were derived. Three of the four
patients had sustained and continuous production of low
levels of reconstituted neutrophils for 6 to 14 months. Of
even greater interest, although still not understood, is the
finding that two of the patients who had liver infections
that resisted cure by conventional methods resolved dur-
ing the course of treatment [64]. This suggests that the
gene therapy approach could also be effective in treating
CGD patients with severe intractable infections, although
more targeted and longer term studies are needed.
Gene therapy trials for CGD in Europe began in 2004
through the collaborative efforts in Frankfurt and Lon-
don. So far, two patients have been treated with retroviral
vector and encouraging results show that both patients
have significant levels of gene corrected cells and are clin-
ically well (personal communication). Gene therapy
holds great promise as an alternative treatment for
patients without suitable marrow donors or where BMT is
not a viable treatment option.
Prospectives
It is estimated that one in 250,000 babies is born with
CGD, although symptoms of the condition may not
appear until after the first few months of age. Early reports
documented the survival of patients beyond 7 years of age
as 21% [65] which has since vastly improved due to
advancement in treatments, and use of prophylactic anti-
bacterials has seen a significant reduction in infectious
complications. Over the last decade there has been
momentous progress in scientific research into the under-
lying mechanisms of CGD. A recent search on the NIH
Pubmed database showed over 2500 scientific publica-
tions on CGD dating back as far as 1959. The European
CGD registry (funded by the CGD Research Trust) cur-
rently contains data on 490 CGD patients that provides a
wealth of information for scientists, clinicians, nurses and
patients alike. In the UK, the CGD Research Trust and
Support Group is an active group who monitor and sup-
port CGD patients based in Britain, in addition to raising
money and funding research into CGD [66]. Improved
diagnosis ensures that patients with CGD are effectively
managed and many people with CGD can carry on a nor-
mal life with few problems.
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